Melanoma CT

Jump to: navigation, search

Melanoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Melanoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Melanoma CT On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Melanoma CT

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Melanoma CT

CDC on Melanoma CT

Melanoma CT in the news

Blogs on Melanoma CT

Directions to Hospitals Treating Melanoma

Risk calculators and risk factors for Melanoma CT

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.

Overview

Melanoma can appear as a soft tissue mass on CT scan. Chest CT scan is recommended for the diagnosis of metastatic lesions in patients who have been diagnosed with stage IA-IV melanoma and for secondary prevention of melanoma in patients who were previously diagnosed with Stage IIB-IV melanoma (annually for 5 years).

CT Scan

References

  1. Brant JM (November 2013). "Breathlessness with pulmonary metastases: a multimodal approach". J Adv Pract Oncol. 4 (6): 415–22. PMID 25032021.
  2. Powell CA (March 2017). "Pulmonary Infiltrates in a Patient With Advanced Melanoma". J. Clin. Oncol. 35 (7): 705–708. doi:10.1200/JCO.2016.69.9793. PMID 28029320.
  3. Perng P, Marcus C, Subramaniam RM (August 2015). "(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis". AJR Am J Roentgenol. 205 (2): 259–70. doi:10.2214/AJR.14.13575. PMID 26204273.
  4. 4.0 4.1 4.2 Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A; et al. (2013). "Melanoma, version 2.2013: featured updates to the NCCN guidelines". J Natl Compr Canc Netw. 11 (4): 395–407. PMID 23584343.

Linked-in.jpg